© 2001 American Academy of Neurology
J. Killestein, MD, N. F. Kalkers,
MD, J. F. Meilof, MD PhD;, F. Barkhof, MD PhD;, R. A. W. van Lier, MD PhD;
and C. H. Polman, MD PhD
From the Department of Neurology (Drs. Killestein, Kalkers, Meilof, and Polman) and the MS-MRI Center (Dr. Barkhof), Vrije Universiteit Medical Center, and the Department of Immunobiology, (Drs. Killestein and van Lier), Centraal Laboratorium Bloedtransfusiedienst, Amsterdam, the Netherlands.
Address correspondence and reprint requests to Dr. C.H. Polman, Department of Neurology, VU Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, the Netherlands; e-mail: CH.Polman@azvu.nl
Reliable laboratory prognostic factors for MS are still lacking.
The predictive value of markers of T-cell activation for long-term disease progression was investigated.
Flow cytometry measurements were correlated to changes in Expanded Disability Status Scale and MR T2 lesion load over 36 months in 14 patients with secondary progressive MS.
A correlation was found between the percentage of tumor necrosis factor--producing CD4+ T cells at baseline and the change in T2 lesion load during 3-year follow-up (r = 0.79, adjusted r2 = 0.59, p = 0.001).